The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

alextherapeutics.com

Founded Year

2018

Stage

Series A | Alive

Total Raised

$4.44M

Last Raised

$3.82M | 4 mos ago

Mosaic Score

+10 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Alex Therapeutics

Alex Therapeutics is a digital therapeutics (DTx) company that designs and develops Software-as-a-Medical-Devices (SaMDs). With the "Alex DTx Platform" and expertise in artificial intelligence and evidence-based psychology, Alex Therapeutics is positioned to deliver reliable DTx products. The company was founded in 2018 and is based in Stockholm, Sweden.

Alex Therapeutics Headquarters Location

Birger Jarlsgatan 57C

Stockholm, 113 56,

Sweden

+46 70-822 11 57

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Alex Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Alex Therapeutics in 1 CB Insights research brief, most recently on Sep 13, 2021.

Expert Collections containing Alex Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alex Therapeutics is included in 4 Expert Collections, including Digital Health.

D

Digital Health

22,342 items

Startups recreating how healthcare is delivered

M

Mental Health Tech

1,353 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Beauty & Personal Care

858 items

These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.

Latest Alex Therapeutics News

Study of Vicore’s DTx for anxiety in IPF patients gets underway

Apr 22, 2022

April 22, 2022 Sweden’s Vicore Pharma has started a clinical trial of a digital therapeutic (DTx) intended to relieve anxiety in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and progressive respiratory disease with no curative treatment. The COMPANION study will test a cognitive behavioural therapy-based DTx called Almee (formerly VP04) – developed in partnership with digital health company Alex Therapeutics – to see if it can reduce the psychological symptom burden in adults diagnosed with IPF . Patients with IPF have an average life expectancy of just three to five years, during which time symptoms like cough, fatigue and shortness of breath get worse, and around two thirds of them report moderate to severe anxiety. Vicore – a specialist in respiratory disease therapies – joined forces with Alex last year to develop a DTx for these patients, with the Swedish drugmaker holding all rights to the therapy in exchange for an upfront payment of around $1 million plus potential milestones and royalties. Almost exactly a year later, the two partners have kicked off their first clinical trial, with the first patient enrolled in the pilot phase of the study, ahead of a pivotal phase due to start in the latter half of the year. It will use a decentralised clinical trial (DCT) model to allow IPF patients to take part remotely. The pilot will help to refine the interactive nature of the CBT session that will be taken forward into the pivotal phase of the US study, said Vicore, which expects results to be available in the first half of 2023. Almee has been designed to provide CBT to IPF patients in parallel to routine consultations with medical professionals to help reduce anxiety and improve their quality of life. If the COMPANION trial is successful, Vicore intends to submit it for FDA approval as a medical device, in the hope of making it available to patients in 2024. If approved, Almee could form part of a differentiated therapy offering for IPF patients alongside Vicore’s drug candidates for IPF. Its pipeline is currently headed by VP01 (also known as C21), billed as a first-in-class oral angiotensin II type 2 receptor (AT2R) agonist, which is in phase 2 development for IPF and phase 3 for COVID-19 and aims to reduce the fibrosis (scarring) associated with the disease. Following after is a new formulation of immune-modulating drug thalidomide, delivered directly to the lungs, which is intended to treat the persistent drug cough associated with IPF. Don't miss your daily pharmaphorum news.

Alex Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alex Therapeutics Rank

  • When was Alex Therapeutics founded?

    Alex Therapeutics was founded in 2018.

  • Where is Alex Therapeutics's headquarters?

    Alex Therapeutics's headquarters is located at Birger Jarlsgatan 57C, Stockholm.

  • What is Alex Therapeutics's latest funding round?

    Alex Therapeutics's latest funding round is Series A.

  • How much did Alex Therapeutics raise?

    Alex Therapeutics raised a total of $4.44M.

  • Who are the investors of Alex Therapeutics?

    Investors of Alex Therapeutics include Sweet Studio, Scale Capital, Hadean Ventures and Bonit Capital.

  • Who are Alex Therapeutics's competitors?

    Competitors of Alex Therapeutics include CureApp and 4 more.

You May Also Like

Kwit Logo
Kwit

Kwit is a mobile app game that uses cognitive and behavioral therapies and evidence-based smoking cessation scientific methods to help users quit smoking and fight the symptoms of withdrawal.

C
CureApp

CureApp is a digital health company that offers a horizontal spread of medical apps for the treatment and management of a range of diseases, which allows patient treatment data to be obtained on a daily basis through mobile devices such as smartphones. This information is then analyzed using algorithms based on known medical information in order to provide personalized guidance for individual patients. Its apps exhibit therapeutic effects against nicotine addiction, NASH (non-alcoholic steatohepatitis remedy), diabetes, depression, and lung cancer. The firm serves clients operating in the healthcare sector. It was founded in 2014 and is based in Tokyo, Japan.

2Morrow Logo
2Morrow

2Morrow is a digital health/digital therapeutic company focused on behaviors that cause chronic disease. The company delivers programs based on the work of respected researchers directly into the hands of people, whenever and wherever they need them via their smartphone.

Quit Genius Logo
Quit Genius

Quit Genius develops a digital clinic that delivers a comprehensive Medication-Assisted Treatment program for multiple addictions. It partners with employers, health plans, PBMs, and individual members, to battle addiction in the workplace across the U.S. and the U.K. The company was founded in 2017 and is based in New York, New York.

Click Therapeutics Logo
Click Therapeutics

Click Therapeutics develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. Click's smoking cessation program is currently available nationwide through a variety of payers, providers, and employers. Click Therapeutics was founded in 2012 and is based in New York, New York.

Pivot Logo
Pivot

Pivot is a digital health company on a mission to use mobile technology, behavioral science, and clinical expertise to engage and empower. The company's Pivot combines wearable tech, clinical expertise, personal coaching, and behavioral science to help people quit smoking.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.